{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:49:39Z","timestamp":1787503779848,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"GlaxoSmithKline Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10637-019-00783-7","type":"journal-article","created":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T16:34:53Z","timestamp":1557246893000},"page":"457-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma"],"prefix":"10.1007","volume":"38","author":[{"given":"Emilie M. J.","family":"van Brummelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Levchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00f3mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Garrido","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Kostorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Orlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan F.","family":"Vansteenkiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Baker-Neblett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Bellovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionel","family":"Mitrica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Phillip","family":"DeYoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4489-2683","authenticated-orcid":false,"given":"Jos\u00e9","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"key":"783_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA (2017) Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 17:475\u2013488","journal-title":"Nat Rev Cancer"},{"key":"783_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of Pemetrexed in combination with Cisplatin versus Cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"783_CR3","doi-asserted-by":"publisher","first-page":"39861","DOI":"10.18632\/oncotarget.9515","volume":"7","author":"C Blackwell","year":"2016","unstructured":"Blackwell C, Sherk C, Fricko M, Ganji G, Barnette M, Hoang B, Tunstead J, Skedzielewski T, Alsaid H, Jucker BM, Minthorn E, Kumar R, DeYoung M (2016) Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230. Oncotarget 7:39861\u201339871","journal-title":"Oncotarget"},{"key":"783_CR4","doi-asserted-by":"publisher","first-page":"25369","DOI":"10.1074\/jbc.M414498200","volume":"280","author":"M Stapelberg","year":"2005","unstructured":"Stapelberg M, Gellert N, Swettenham E, Tomasetti M, Witting PK, Procopio A, Neuzil J (2005) \u03b1-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor Autocrine loop. J Biol Chem 280:25369\u201325376","journal-title":"J Biol Chem"},{"key":"783_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116\u2013129","journal-title":"Nat Rev Cancer"},{"key":"783_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cytogfr.2005.01.003","volume":"16","author":"R Grose","year":"2005","unstructured":"Grose R, Dickson C (2005) Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16:179\u2013186","journal-title":"Cytokine Growth Factor Rev"},{"key":"783_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1248\/bpb.30.1819","volume":"30","author":"N Itoh","year":"2007","unstructured":"Itoh N (2007) The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 30:1819\u20131825","journal-title":"Biol Pharm Bull"},{"key":"783_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","volume":"3","author":"MV Dieci","year":"2013","unstructured":"Dieci MV, Arnedos M, Andre F, Soria JC (2013) Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 3:264\u2013279","journal-title":"Cancer Discov"},{"key":"783_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10637-017-0514-4","volume":"36","author":"T Nishina","year":"2018","unstructured":"Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T (2018) Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Investig New Drugs 36:424\u2013434","journal-title":"Investig New Drugs"},{"key":"783_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"L Nogova","year":"2017","unstructured":"Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J (2017) Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol 35:157\u2013165","journal-title":"J Clin Oncol"},{"key":"783_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","volume":"12","author":"M Michael","year":"2017","unstructured":"Michael M, Bang Y-J, Park YS, Kang YK, Kim TM, Hamid O, Thornton D, Tate SC, Raddad E, Tie J (2017) A phase 1 study of LY2874455, an Oral selective pan-FGFR inhibitor, in patients with advanced Cancer. Target Oncol 12:463\u2013474","journal-title":"Target Oncol"},{"key":"783_CR12","doi-asserted-by":"publisher","first-page":"178ra39","DOI":"10.1126\/scitranslmed.3005414","volume":"5","author":"TC Harding","year":"2013","unstructured":"Harding TC, Long L, Palencia S, Zhang H, Sadra A, Hestir K et al (2013) Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of Cancer. Sci Transl Med 5:178ra39","journal-title":"Sci Transl Med"},{"key":"783_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdv591","volume":"27","author":"AW Tolcher","year":"2016","unstructured":"Tolcher AW, Papadopoulos KP, Patnaik A, Wilson K, Thayer S, Zanghi J, Gemo AT, Kavanaugh WM, Keer HN, LoRusso PM (2016) A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol 27:526\u2013532","journal-title":"Ann Oncol"},{"key":"783_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13287-017-0573-7","volume":"8","author":"A Pattarozzi","year":"2017","unstructured":"Pattarozzi A, Carra E, Favoni RE, W\u00fcrth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A (2017) The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. Stem Cell Res Ther 8:119","journal-title":"Stem Cell Res Ther"},{"key":"783_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","volume":"190","author":"K Schelch","year":"2014","unstructured":"Schelch K, Hoda MA, Klikovits T, M\u00fcnzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M (2014) Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. Am J Respir Crit Care Med 190:763\u2013772","journal-title":"Am J Respir Crit Care Med"},{"key":"783_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","volume":"12","author":"LA Marek","year":"2014","unstructured":"Marek LA, Hinz TK, von Massenhausen A, Olszewski KA, Kleczko EK, Boehm D et al (2014) Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res 12:1460\u20131469","journal-title":"Mol Cancer Res"},{"key":"783_CR17","unstructured":"U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM) (2001) Guidance for Industry: Bioanalytical Method Validation"},{"key":"783_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10585-004-3150-2","volume":"21","author":"B Davidson","year":"2004","unstructured":"Davidson B, Vintman L, Zcharia E, Bedrossian C, Berner A, Nielsen S, Ilan N, Vlodavsky I, Reich R (2004) Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 21:469\u2013476","journal-title":"Clin Exp Metastasis"},{"key":"783_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","volume":"179","author":"Q Li","year":"2011","unstructured":"Li Q, Wang W, Yamada T, Matsumoto K, Sakai K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S (2011) Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 179:1483\u20131493","journal-title":"Am J Pathol"},{"key":"783_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","volume":"189","author":"S Kumar-Singh","year":"1999","unstructured":"Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E (1999) Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 189:72\u201378","journal-title":"J Pathol"},{"key":"783_CR21","first-page":"47","volume":"1","author":"MH Hanigan","year":"2003","unstructured":"Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47\u201361","journal-title":"Cancer Ther"},{"key":"783_CR22","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivi\u00e8re F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin Cisplatin Pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405\u20131414","journal-title":"Lancet"},{"key":"783_CR23","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","volume":"23","author":"PK Paik","year":"2017","unstructured":"Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, Landers D, Frewer P, Brooks N, Andr\u00e9 F (2017) A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers. Clin Cancer Res 23:5366\u20135373","journal-title":"Clin Cancer Res"},{"key":"783_CR24","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","volume":"33","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC (2015) Phase I dose-escalation study of JNJ-42756493, an Oral Pan\u2013fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 33:3401\u20133408","journal-title":"J Clin Oncol"},{"key":"783_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, el-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced Cholangiocarcinoma. J Clin Oncol 36:276\u2013282","journal-title":"J Clin Oncol"},{"key":"783_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX (2017) Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive Cholangiocarcinoma. Cancer Discov 7:252\u2013263","journal-title":"Cancer Discov"},{"key":"783_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","volume":"24","author":"JM Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld J, Iorio F, Kolluri K, Garnett M, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C (2018) Comprehensive Pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition. Clin Cancer Res 24:84\u201394","journal-title":"Clin Cancer Res"},{"key":"783_CR28","doi-asserted-by":"publisher","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","volume":"6","author":"E Marcq","year":"2017","unstructured":"Marcq E, Siozopoulou V, De Waele J, van Audenaerde J, Zwaenepoel K, Santermans E et al (2017) Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology 6:e1261241","journal-title":"Oncoimmunology"},{"key":"783_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E (2017) Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18:623\u2013630","journal-title":"Lancet Oncol"},{"key":"783_CR30","doi-asserted-by":"crossref","unstructured":"Zalcman G, Mazieres J, Greillier L, Lantuejoul S, D\u00f4 P, Bylicki O et al (2017) LBA58_PR second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: up-dated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Oncol 28 Issue suppl_5, mdx440.074","DOI":"10.1093\/annonc\/mdx440.074"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00783-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00783-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00783-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:43:36Z","timestamp":1678542216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00783-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00783-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"10 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. D\u00f3mine reports receiving speakers\u2019 bureau honoraria and is a consultant\/advisory board member for AstraZeneca (AZ), Bristol-Myers Squibb (BMS), Boehringer Ingelheim (BI), Celgene, MSD, Roche-Genentech, and AbbVie.D.A. Fennell reports receiving commercial research grants from Astex, Bayer, and BI, speakers\u2019 bureau honoraria from BI and BMS and is a consultant\/advisory board member for Roche, Bayer, Aldeyra Therapeutics, AbbVie, and BMS.H.L. Kindler reports receiving commercial research grants from Aduro Biotech, AZ, Bayer, GlaxoSmithKline (GSK), Merck, MedImmune, Verastem, BMS, Eli Lilly, Polaris, and Deciphera and is a consultant\/advisory board member for Aduro Biotech, MedImmune, Bayer, Celgene, GSK, AZ, Merck, BMS, BI, Ipsen, Erytech Pharma, Five Prime Therapeutics, and Paredox Therapeutics.S. Gadgeel is a consultant\/advisory board member for AZ, Roche-Genentech, Takeda, BMS, and AbbVie.P. Garrido Lopez reports receiving commercial research grants from GSK, Celgene, Sanofi, PharmaMar, Theradex, Roche, BMS, Lilly, Guardant, Sysmex, Takeda, AZ, BI, and Novartis and is a consultant\/advisory board member for Roche, MSD, BMS, BI, Pfizer, Abbvie, Guardant,Novartis, Lilly, AZ, Janssen, Sysmex, Blueprint Medicine, and Takeda.D. Morgensztern is a consultant\/advisory board member for Takeda, AbbVie, BMS, and PharmaMar.M.G. Zauderer is an employee of MSKCC and MSKCC has an institutional collaboration agreement with IBM for Watson for Oncology and receives royalties from IBM, is the Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, reports receiving commercial research grants from MedImmune, Epizyme, Polaris, Sellas Life Sciences, BMS, and Millenium, and is a consultant\/advisory board member for Epizyme and Aldeyra Therapeutics.J.F. Vansteenkiste reports receiving research funding\/honoraria from MSD, AZ, BMS, BI, and Roche and is a\n              consultant\/advisory board member for AZ, BMS, BI, MSD, and Roche.K. Baker-Neblett, X. Wang, L. Yan, I. Mitrica, and M.P. DeYoung are employees of and hold ownership interest in GlaxoSmithKline. J. Vasquez is an employee of GlaxoSmithKline.D.I. Bellovin is an employee of and holds ownership interest in Five Prime Therapeutics.J.H.M. Schellens is an employee of and holds ownership interest in Modra Pharmaceuticals and is a consultant\/advisory board member for Debiopharm.J.M. Trigo reports receiving speakers\u2019 bureau honoraria from BMS and BI and is a consultant\/advisory board member for BMS, BI, Merck, and Takeda.No potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}